These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 18598762)
1. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues. Han Y; Riwanto M; Go ML; Ee PL Eur J Pharm Sci; 2008 Sep; 35(1-2):30-41. PubMed ID: 18598762 [TBL] [Abstract][Full Text] [Related]
2. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Liu XL; Tee HW; Go ML Bioorg Med Chem; 2008 Jan; 16(1):171-80. PubMed ID: 17964170 [TBL] [Abstract][Full Text] [Related]
3. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein). Sim HM; Lee CY; Ee PL; Go ML Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288 [TBL] [Abstract][Full Text] [Related]
4. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Juvale K; Pape VF; Wiese M Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540 [TBL] [Abstract][Full Text] [Related]
5. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473 [TBL] [Abstract][Full Text] [Related]
6. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302 [TBL] [Abstract][Full Text] [Related]
7. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939 [TBL] [Abstract][Full Text] [Related]
8. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). Shen H; Lee FY; Gan J J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849 [TBL] [Abstract][Full Text] [Related]
9. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658 [TBL] [Abstract][Full Text] [Related]
10. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). Gupta A; Zhang Y; Unadkat JD; Mao Q J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902 [TBL] [Abstract][Full Text] [Related]
12. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652 [TBL] [Abstract][Full Text] [Related]
14. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965 [TBL] [Abstract][Full Text] [Related]
15. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP). González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460 [TBL] [Abstract][Full Text] [Related]
16. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport. Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106 [TBL] [Abstract][Full Text] [Related]
17. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase. Ji N; Yuan J; Liu J; Tian S Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767 [TBL] [Abstract][Full Text] [Related]
18. A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2). Mahringer A; Delzer J; Fricker G Eur J Pharm Biopharm; 2009 Aug; 72(3):605-13. PubMed ID: 19572416 [TBL] [Abstract][Full Text] [Related]
19. Interactions of cyclosporin a with breast cancer resistance protein. Xia CQ; Liu N; Miwa GT; Gan LS Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]